FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000402465> ?p ?o ?g. }

• W2000402465 endingPage "1349" @default.
• W2000402465 startingPage "1348" @default.
• W2000402465 abstract "HomeCirculationVol. 107, No. 10NO Balance Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBNO BalanceRegulation of the Cytoskeleton in Congestive Heart Failure by Nitric Oxide Cornel Badorff and Stefanie Dimmeler Cornel BadorffCornel Badorff From Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany. Search for more papers by this author and Stefanie DimmelerStefanie Dimmeler From Molecular Cardiology, Department of Internal Medicine IV, University of Frankfurt, Frankfurt, Germany. Search for more papers by this author Originally published18 Mar 2003https://doi.org/10.1161/01.CIR.0000057859.91134.ADCirculation. 2003;107:1348–1349Congestive heart failure is a leading cause of cardiovascular mortality in the United States and Europe.1 Clinically, this syndrome is characterized by water retention and often left ventricular dilatation with poor systolic contractility. Etiologically, congestive heart failure can be of genetic or acquired origin. In 1993, 2 groups independently reported mutations in the cytoskeletal protein dystrophin as the cause of X-linked dilated cardiomyopathy, a rare inheritable disease that leads to enlargement of ventricular dimensions and to congestive heart failure.1 Over the last decade, the pathophysiological relevance of the cardiac myocyte cytoskeleton for the development of congestive heart failure is being increasingly recognized.See p 1424For a coordinated contractile function of the heart, the mechanical forces generated within the sarcomeres of individual cardiac myocytes are transmitted to the extracellular matrix.2 For this purpose, cardiac myocytes are equipped with a specialized extrasarcomeric cytoskeleton. The cardiac myocyte cytoskeleton acts as a “scaffold” that provides mechanical stability to transmit the periodic shortening of the sarcomeres to adjacent cardiac myocytes.1 Additionally, the cytoskeleton possesses important signaling properties.3The critical importance of an intact cytoskeleton for normal cardiac function in humans and rodents is highlighted by genetic defects in the cytoskeletal proteins titin, actin, dystrophin, sarcoglycans, and others, all of which cause dilated cardiomyopathy with congestive heart failure in patients.1,2,4 In the cardiomyopathic hamster, a δ-sarcoglycan deletion has been identified as disease-causing, and targeted deletion of the muscle LIM protein (MLP) in mice results in a dilated cardiomyopathy phenotype.5MLP is a muscle-specific, LIM-domain only cytoskeletal adaptor protein that is localized to the Z discs, binds the Z disc protein α-actinin, and binds to telethonin, a component of the titin complex in the sarcolemma.5,6 MLP is required for muscle differentiation,7 and targeted MLP ablation leads to congestive heart failure with cytoskeletal disruption and premature death in a mouse model.5 Importantly, MLP missense mutations occur in a subset of human dilated cardiomyopathy.6These studies lead to the paradigm that hereditary dilated cardiomyopathy can result from defective transmission of mechanical force from the sarcomere to the extracellular matrix.1 Similarly, cytoskeletal disruption may pathogenetically contribute to acquired forms of congestive heart failure, such as ischemic cardiomyopathy in humans and enterovirus-induced cardiomyopathy in mice.8Nitric oxide (NO) is a small gaseous molecule that mediates multiple signaling pathways in the heart. NO is generated from l-arginine by 3 different isoforms of nitric oxide synthase (NOS).9 In contrast to the neuronal (NOSI) and endothelial (NOSIII) isoform, the inducible NOS isoform (NOSII) synthesizes large NO amounts independent of calcium. In addition to acting as a signaling molecule, NO can react with O2− to form peroxynitrite (ONOO−), a cell-toxic reactive nitrogen intermediate that leads to target protein tyrosine residue nitration (NO-Y).10Recent studies have demonstrated that NO can clearly modulate cytoskeletal functions. In high concentrations, NO resulted in a reduction of myofilament responsiveness to calcium in cardiac myocytes via the cGMP-dependent activation of the protein kinase G (PKG).11 In chick sensory neurons, NO causes microtubule reconfiguration and axonal retraction.12 NO additionally was shown to directly S-nitrosylate the cytoskeletal proteins actin and tubulin.13 In glomerular mesangial cells, addition of NO donors results in a change of the cellular shape and a disassembly of filamentous actin (F-actin).14 Interestingly, in intestinal cells, added ONOO− also leads to disassembly of the F-actin cytoskeleton and actin nitration, both of which could be rescued by radical scavengers.10,15 These results show that the adverse effects of NO on the cytoskeleton are mediated, at least in part, by the reactive intermediates O2− and ONOO−. Therefore, the balance between NO versus O2− and ONOO−, which in turn is influenced by the availability of NOS cofactors and scavenging mechanisms, seems to be important in the cytoskeletal regulation by NO.In human dilated cardiomyopathy and congestive heart failure, increased systemic NO production and enhanced myocardial NOSII mRNA and NOSII enzymatic activity have been reported.16 However, the pathophysiological role of NO in this context remains controversial, and NO has been referred to as a “double-edged sword.” Heger et al17 reported that increased cardiac iNOS expression did not alter cardiac structure and function. In contrast, Mungrue et al18 recently described that conditional cardiac overexpression of NOSII in transgenic mice leads to an increased cardiac ONOO− production and NO-Y formation in the animals’ hearts. This was associated with a mild inflammatory infiltrate, cardiac fibrosis, hypertrophy, chamber dilatation, and, albeit infrequently, congestive heart failure.18 Although the cytoskeleton of these transgenic mice were not directly assessed, the development of cardiac fibrosis suggests some degree of cytoskeletal reorganization.18 The different phenotypes of the transgenic mice might be explained by the experimental setting. One may speculate that the non-conditional approach used by Heger et al17 may have allowed for the upregulation of compensatory mechanisms, which may shift the balance between NO and ONOO−. Indeed, in the conditional iNOS transgenic animals, where a phenotype was observed, drastic increases in ONOO− were demonstrated.18In the current issue of Circulation, Heineke et al19 report that addition of the NO donor S-Nitro-N-Acetyl-Penicillamine to rat neonatal ventricular cardiac myocytes reduced the endothelin-1–induced MLP upregulation by approximately 50%. Similarly, induction of NOSII in cardiac myocytes also significantly reduced the endothelin-1–induced MLP upregulation. The effects were partially rescued by radical scavenging superoxide dismutase and were reproduced by the addition of ONOO−. This suggests that NO suppressed MLP expression in part through ONOO− formation. However, cGMP-dependent activation of PKG also contributed to the phenotype, as demonstrated by the use of cardiac myocytes adenovirally transduced with a dominant-negative PKG mutant.19 Importantly, the expression levels of NOSII and MLP displayed an inverse correlation in human hearts with congestive heart failure due to ischemic or dilated cardiomyopathy. Finally, antisense MLP downregulation suppressed cardiac myocyte hypertrophy and, in turn, MLP overexpression was sufficient for some aspects of cardiomyocyte hypertrophy.19These data provide the first molecular link between NO/ONOO− and a component of the cardiac myocyte cytoskeleton crucial for a normal function of the heart. Together with in vivo results,18 these data support the concept that the adverse effects of ONOO− on cardiac myocytes are, at least in part, mediated through the cardiac myocyte cytoskeleton. This represents further evidence for the “final common pathway hypothesis” postulating that cytoskeletal abnormalities underlie or contribute to many forms of congestive heart failure.1 In this regard, it is important to note that a 50% reduction of MLP expression in human heart failure has been independently described.20 It is tempting to speculate that downregulation of MLP is functionally important in the setting of human heart failure, although MLP+/− mice with 50% MLP expression levels do not display a dilated cardiomyopathy phenotype at baseline.5 Further experiments are required to determine the effects of partial MLP deficiency in various pathological conditions, such as myocardial infarction or pressure overload. Nevertheless, the study by Heineke et al19 provides an important molecular insight how NO/ONOO− regulates the cardiac myocyte cytoskeleton, a critical player in congestive heart failure.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.Drs Badorff and Dimmeler are supported by the Deutsche Forschunggemenschaft (Ba 1668/3–1) and the Sonderforschungsbereich (SFB 553, Projects C2 and B6), respectively.FootnotesCorrespondence to Stefanie Dimmeler, Dept. of Molecular Cardiology, University of Frankfurt, Theodor Stern-Kai 7, 60590 Frankfurt, Germany. E-mail [email protected] References 1 Towbin JA, Bowles NE. The failing heart. Nature. 2002; 415: 227–233.CrossrefMedlineGoogle Scholar2 Hoshijima M, Chien KR. Mixed signals in heart failure: cancer rules. J Clin Invest. 2002; 109: 849–855.CrossrefMedlineGoogle Scholar3 Albrecht DE, Froehner SC. Syntrophins and dystrobrevins: defining the dystrophin scaffold at synapses. Neurosignals. 2002; 11: 123–129.CrossrefMedlineGoogle Scholar4 Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001; 104: 557–567.CrossrefMedlineGoogle Scholar5 Arber S, Hunter JJ, Ross J Jr, et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell. 1997; 88: 393–403.CrossrefMedlineGoogle Scholar6 Knoll R, Hoshijima M, Hoffman HM, et al. The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy. Cell. 2002; 111: 943–955.CrossrefMedlineGoogle Scholar7 Arber S, Halder G, Caroni P, Muscle LIM protein, a novel essential regulator of myogenesis, promotes myogenic differentiation. Cell. 1994; 79: 221–231.CrossrefMedlineGoogle Scholar8 Xiong D, Lee GH, Badorff C, et al. Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: a genetic predisposition to viral heart disease. Nat Med. 2002; 8: 872–877.CrossrefMedlineGoogle Scholar9 Moncada S, Higgs A, The L-arginine-nitric oxide pathway. N Engl J Med. 1993; 329: 2002–2012.CrossrefMedlineGoogle Scholar10 Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271: C1424–1437.CrossrefMedlineGoogle Scholar11 Vila-Petroff MG, Younes A, Egan J, et al. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res. 1999; 84: 1020–1031.CrossrefMedlineGoogle Scholar12 He Y, Yu W, Baas PW. Microtubule reconfiguration during axonal retraction induced by nitric oxide. J Neurosci. 2002; 22: 5982–5991.CrossrefMedlineGoogle Scholar13 Jaffrey SR, Erdjument-Bromage H, Ferris CD, et al. Protein S-nitrosylation: a physiological signal for neuronal nitric oxide. Nat Cell Biol. 2001; 3: 193–197.CrossrefMedlineGoogle Scholar14 Sandau KB, Gantner F, Brune B. Nitric oxide-induced F-actin disassembly is mediated via cGMP, cAMP, and protein kinase A activation in rat mesangial cells. Exp Cell Res. 2001; 271: 329–336.CrossrefMedlineGoogle Scholar15 Banan A, Zhang L, Fields JZ, et al. PKC-zeta prevents oxidant-induced iNOS upregulation and protects the microtubules and gut barrier integrity. Am J Physiol Gastrointest Liver Physiol. 2002; 283: G909–G922.CrossrefMedlineGoogle Scholar16 de Belder AJ, Radomski MW, Why HJ, et al. Nitric oxide synthase activities in human myocardium. Lancet. 1993; 341: 84–85.CrossrefMedlineGoogle Scholar17 Heger J, Godecke A, Flogel U, et al. Cardiac-specific overexpression of inducible nitric oxide synthase does not result in severe cardiac dysfunction. Circ Res. 2002; 90: 93–99.CrossrefMedlineGoogle Scholar18 Mungrue IN, Gros R, You X, et al. Cardiomyocyte overexpression of iNOS in mice results in peroxynitrite generation, heart block, and sudden death. J Clin Invest. 2002; 109: 735–743.CrossrefMedlineGoogle Scholar19 Heineke J, Kempf T, Kraft T, et al. Downregulation of cytoskeletal muscle LIM protein by nitric oxide: impact on cardiac myocyte hypertrophy. Circulation. 2003; 107: 1424–1431.LinkGoogle Scholar20 Zolk O, Caroni P, Bohm M. Decreased expression of the cardiac LIM domain protein MLP in chronic human heart failure. Circulation. 2000; 101: 2674–2677.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Hritzo B, Aghdam S, Legesse B, Kaur A, Cao M, Boerma M, Chakraborty N, Dimitrov G, Gautam A, Hammamieh R, Wilkins W, Tsioplaya A, Holmes-Hampton G and Moroni M (2021) Late Health Effects of Partial Body Irradiation Injury in a Minipig Model Are Associated with Changes in Systemic and Cardiac IGF-1 Signaling, International Journal of Molecular Sciences, 10.3390/ijms22063286, 22:6, (3286) Wu Q, Xiao Y, Duan M, Yuan Y, Jiang X, Yang Z, Liao H, Deng W and Tang Q (2018) Aucubin protects against pressure overload-induced cardiac remodelling via the β 3 -adrenoceptor-neuronal NOS cascades , British Journal of Pharmacology, 10.1111/bph.14164, 175:9, (1548-1566), Online publication date: 1-May-2018. Chavoshan B, Fournier M, Lewis M, Porszasz J, Storer T, Da X, Rambod M and Casaburi R (2012) Testosterone and resistance training effects on muscle nitric oxide synthase isoforms in COPD men, Respiratory Medicine, 10.1016/j.rmed.2011.07.018, 106:2, (269-275), Online publication date: 1-Feb-2012. Yan X, Schuldt A, Price R, Amende I, Liu F, Okoshi K, Ho K, Pope A, Borg T, Lorell B and Morgan J (2008) Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT 2 receptors in ventricular myocytes , American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00174.2006, 294:3, (H1274-H1281), Online publication date: 1-Mar-2008. Schulz R, Rassaf T, Massion P, Kelm M and Balligand J (2005) Recent advances in the understanding of the role of nitric oxide in cardiovascular homeostasis, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2005.04.005, 108:3, (225-256), Online publication date: 1-Dec-2005. Booz G (2005) Putting the Brakes on Cardiac Hypertrophy, Hypertension, 45:3, (341-346), Online publication date: 1-Mar-2005. Meyers D and Cuneo R (2003) Controversies Regarding the Effects of Growth Hormone on the Heart, Mayo Clinic Proceedings, 10.4065/78.12.1521, 78:12, (1521-1526), Online publication date: 1-Dec-2003. March 18, 2003Vol 107, Issue 10 Advertisement Article InformationMetrics https://doi.org/10.1161/01.CIR.0000057859.91134.ADPMID: 12642351 Originally publishedMarch 18, 2003 KeywordsEditorialsheat failuremyocytesnitric oxidecellsPDF download Advertisement" @default.
• W2000402465 created "2016-06-24" @default.
• W2000402465 creator A5025706940 @default.
• W2000402465 creator A5046731396 @default.
• W2000402465 date "2003-03-18" @default.
• W2000402465 modified "2023-09-26" @default.
• W2000402465 title "NO Balance" @default.
• W2000402465 cites W1492951734 @default.
• W2000402465 cites W1821918060 @default.
• W2000402465 cites W1966485417 @default.
• W2000402465 cites W2008972531 @default.
• W2000402465 cites W2015057079 @default.
• W2000402465 cites W2026182775 @default.
• W2000402465 cites W2032260752 @default.
• W2000402465 cites W2036754849 @default.
• W2000402465 cites W2058099844 @default.
• W2000402465 cites W2059102370 @default.
• W2000402465 cites W2068671266 @default.
• W2000402465 cites W2086578965 @default.
• W2000402465 cites W2112064082 @default.
• W2000402465 cites W2136213673 @default.
• W2000402465 cites W2313326603 @default.
• W2000402465 cites W4246057271 @default.
• W2000402465 cites W4255767289 @default.
• W2000402465 doi "https://doi.org/10.1161/01.cir.0000057859.91134.ad" @default.
• W2000402465 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12642351" @default.
• W2000402465 hasPublicationYear "2003" @default.
• W2000402465 type Work @default.
• W2000402465 sameAs 2000402465 @default.
• W2000402465 citedByCount "10" @default.
• W2000402465 countsByYear W20004024652012 @default.
• W2000402465 countsByYear W20004024652018 @default.
• W2000402465 countsByYear W20004024652021 @default.
• W2000402465 crossrefType "journal-article" @default.
• W2000402465 hasAuthorship W2000402465A5025706940 @default.
• W2000402465 hasAuthorship W2000402465A5046731396 @default.
• W2000402465 hasBestOaLocation W20004024651 @default.
• W2000402465 hasConcept C126322002 @default.
• W2000402465 hasConcept C142669718 @default.
• W2000402465 hasConcept C1491633281 @default.
• W2000402465 hasConcept C164705383 @default.
• W2000402465 hasConcept C207200792 @default.
• W2000402465 hasConcept C2776383484 @default.
• W2000402465 hasConcept C2778198053 @default.
• W2000402465 hasConcept C2778797674 @default.
• W2000402465 hasConcept C2779030066 @default.
• W2000402465 hasConcept C2780394045 @default.
• W2000402465 hasConcept C3018686881 @default.
• W2000402465 hasConcept C54355233 @default.
• W2000402465 hasConcept C68731436 @default.
• W2000402465 hasConcept C71924100 @default.
• W2000402465 hasConcept C86803240 @default.
• W2000402465 hasConcept C90671521 @default.
• W2000402465 hasConceptScore W2000402465C126322002 @default.
• W2000402465 hasConceptScore W2000402465C142669718 @default.
• W2000402465 hasConceptScore W2000402465C1491633281 @default.
• W2000402465 hasConceptScore W2000402465C164705383 @default.
• W2000402465 hasConceptScore W2000402465C207200792 @default.
• W2000402465 hasConceptScore W2000402465C2776383484 @default.
• W2000402465 hasConceptScore W2000402465C2778198053 @default.
• W2000402465 hasConceptScore W2000402465C2778797674 @default.
• W2000402465 hasConceptScore W2000402465C2779030066 @default.
• W2000402465 hasConceptScore W2000402465C2780394045 @default.
• W2000402465 hasConceptScore W2000402465C3018686881 @default.
• W2000402465 hasConceptScore W2000402465C54355233 @default.
• W2000402465 hasConceptScore W2000402465C68731436 @default.
• W2000402465 hasConceptScore W2000402465C71924100 @default.
• W2000402465 hasConceptScore W2000402465C86803240 @default.
• W2000402465 hasConceptScore W2000402465C90671521 @default.
• W2000402465 hasIssue "10" @default.
• W2000402465 hasLocation W20004024651 @default.
• W2000402465 hasLocation W20004024652 @default.
• W2000402465 hasOpenAccess W2000402465 @default.
• W2000402465 hasPrimaryLocation W20004024651 @default.
• W2000402465 hasRelatedWork W1489783725 @default.
• W2000402465 hasRelatedWork W1506200166 @default.
• W2000402465 hasRelatedWork W2039318446 @default.
• W2000402465 hasRelatedWork W2080531066 @default.
• W2000402465 hasRelatedWork W2373994074 @default.
• W2000402465 hasRelatedWork W2748952813 @default.
• W2000402465 hasRelatedWork W2780146991 @default.
• W2000402465 hasRelatedWork W2896609434 @default.
• W2000402465 hasRelatedWork W2899084033 @default.
• W2000402465 hasRelatedWork W3012411836 @default.
• W2000402465 hasVolume "107" @default.
• W2000402465 isParatext "false" @default.
• W2000402465 isRetracted "false" @default.
• W2000402465 magId "2000402465" @default.
• W2000402465 workType "article" @default.